The Federal Circuit recently ruled against Teva Pharmaceuticals, an Israeli drugmaker, in its effort to delay the enforcement of an injunction requiring the removal of its inhaler patents from the U.S. Food and Drug Administration’s Orange Book. This legal development comes as Teva prepares to appeal the decision to the U.S. Supreme Court. The Federal Circuit’s refusal to pause the injunction could have significant implications for Teva’s ongoing patent litigation strategies and its business interests related to the inhaler products at issue.
For further details on this case, legal professionals can review the information provided by Law360.